Cargando…

Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden

BACKGROUND: Voriconazole is well established as standard treatment for invasive aspergillosis (IA). In 2017, isavuconazole, a new antifungal from the azole class, with a broader pathogen spectrum, was introduced in Sweden. A model has therefore been developed to compare the cost-effectiveness of isa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Floros, Lefteris, Kuessner, Daniel, Posthumus, Jan, Bagshaw, Emma, Sjölin, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371439/ https://www.ncbi.nlm.nih.gov/pubmed/30744563 http://dx.doi.org/10.1186/s12879-019-3683-2

Ejemplares similares

Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK
por: Bagshaw, Emma, et al.
Publicado: (2018)

Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis
por: Harrington, Rachel, et al.
Publicado: (2016)

610. Voriconazole versus isavuconazole in patients with invasive aspergillosis: a retrospective study in a medically insured population across the United States
por: Chan, Sophea, et al.
Publicado: (2023)

Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials
por: Andes, David R., et al.
Publicado: (2018)

358. Comparison of Voriconazole (VORI), Isavuconazole (ISAV), and Posaconazole (POSA) in the Initial Treatment of Patients With Invasive Aspergillosis (IA)
por: Cheng, Matthew P, et al.
Publicado: (2018)

Voriconazole-refractory invasive aspergillosis
por: Park, Se Yoon, et al.
Publicado: (2017)

Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections
por: Donnelley, Monica A, et al.
Publicado: (2016)

Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain
por: Grau, Santiago, et al.
Publicado: (2016)

Antibacterials/isavuconazole/voriconazole: Lack of efficacy: case report
Publicado: (2020)

1211 A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole versus Voriconazole in Patients with Invasive Mold Disease (SECURE): Outcomes in Invasive Aspergillosis Patients
por: Kontoyiannis, Dimitrios, et al.
Publicado: (2014)

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi
por: Desai, Amit V., et al.
Publicado: (2017)

Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy
por: Jenks, Jeffrey D, et al.
Publicado: (2018)

The cost‐effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain
por: Azanza, José Ramón, et al.
Publicado: (2020)

Management of invasive aspergillosis in patients with COPD: Rational use of voriconazole
por: Ader, Florence, et al.
Publicado: (2009)

Amphotericin-B-liposomal/isavuconazole/voriconazole: Lack of efficacy: 6 case report
Publicado: (2022)

Isavuconazole/piperacillin/tazobactam/voriconazole: Drug-induced liver injury: case report
Publicado: (2022)

Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations
por: Natesan, Suganthini Krishnan, et al.
Publicado: (2016)

Pharmacology and metabolism of voriconazole and posaconazole in the treatment of invasive aspergillosis-review of the literature
por: Sandherr, M, et al.
Publicado: (2011)

Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin - review of the literature
por: Karthaus, M
Publicado: (2011)

Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain
por: Ostermann, Helmut, et al.
Publicado: (2014)

850. Real-world effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients
por: Qiu, Ye, et al.
Publicado: (2023)

Orbital Aspergillosis: Voriconazole – The New Standard Treatment?
por: Ohlstein, Derek H., et al.
Publicado: (2012)

Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies
por: Krueger, Kem P, et al.
Publicado: (2009)

An observational efficacy and safety analysis of the treatment of acute invasive aspergillosis using voriconazole
por: Jacobs, F., et al.
Publicado: (2011)

1169. In Vitro Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial
por: Castanheira, Mariana, et al.
Publicado: (2020)

Short course of voriconazole therapy as a risk factor for relapse of invasive pulmonary aspergillosis
por: Shin, Dong Hoon, et al.
Publicado: (2020)

Voriconazole: Lack of efficacy during treatment of invasive pulmonary aspergillosis: 2 case reports
Publicado: (2021)

Therapeutic Drug Monitoring of Sputum Voriconazole in Pulmonary Aspergillosis
por: Sarfati, Sacha, et al.
Publicado: (2022)

P059 The overexpression of efflux pump gene cdr1B resulting in voriconazole- and isavuconazole- resistance in Aspergillus fumigatus recovered from a patient with chronic pulmonary aspergillosis in China
por: Liang, Tianyu, et al.
Publicado: (2022)

Safety, Efficacy, and Exposure–Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis
por: Martin, Judith M., et al.
Publicado: (2017)

1291. Safety of Isavuconazole Compared with Voriconazole as Primary Antifungal Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients
por: Bogler, Yael, et al.
Publicado: (2020)

Therapeutic Drug Monitoring of Isavuconazole: Serum Concentration Variability and Success Rates for Reaching Target in Comparison with Voriconazole
por: Risum, Malene, et al.
Publicado: (2021)

Issues in the management of invasive pulmonary aspergillosis in non-neutropenic patients in the intensive care unit: A role for isavuconazole
por: Bassetti, Matteo, et al.
Publicado: (2018)

Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial
por: Perfect, John R., et al.
Publicado: (2018)

Tissue Distribution and Penetration of Isavuconazole at the Site of Infection in Experimental Invasive Aspergillosis in Mice with Underlying Chronic Granulomatous Disease
por: Lee, Annie, et al.
Publicado: (2019)

Decreased isavuconazole trough concentrations in the treatment of invasive aspergillosis in an adult patient receiving extracorporeal membrane oxygenation support
por: Miller, Michelle, et al.
Publicado: (2022)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis With Isavuconazole: Case Report and Review of the Literature
por: Jacobs, Samantha E., et al.
Publicado: (2017)

Isavuconazole for invasive fungal infections
Publicado: (2020)

Invasive maxillary sinus aspergillosis: A case report successfully treated with voriconazole and surgical debridement
por: Peral-Cagigal, Beatriz, et al.
Publicado: (2014)

Posaconazole achieves prompt recovery of voriconazole-induced liver injury in a case of invasive aspergillosis
por: Martínez-Casanova, Javier, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_67i67vnf2prnp6s5i7cs9d85r2